QQ客服 官方微博 反馈留言

	Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial
	Duan, Jian-Chun; Wang, Zhi-Jie; Lin, Lin; Li, Jun-Ling; Wang, Yan; Bai, Hua; Hu, Xing-Sheng; Liu, Yu-Tao; Hao, Xue-Zhi; Wang, Hong-Yu
	2019
卷号	37期号:4页码:731-737
关键词	Apatinib Docetaxel Lung adenocarcinoma Wild-type EGFR
ISSN号	0167-6997
DOI	10.1007/s10637-019-00735-1
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6344977
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Duan, Jian-Chun,Wang, Zhi-Jie,Lin, Lin,et al. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial[J],2019,37(4):731-737.
APA	Duan, Jian-Chun.,Wang, Zhi-Jie.,Lin, Lin.,Li, Jun-Ling.,Wang, Yan.,...&Wang, Jie.(2019).Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.,37(4),731-737.
MLA	Duan, Jian-Chun,et al."Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial".37.4(2019):731-737.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。